Assessment of Quality of Life During Chemotherapy

References

• Tannock IF. Treating the patient, not just the cancer. N Engl J Med 1987; 317: 1534–5.
   PubMedGoogle Scholar
• Izsak FC, Medalie JH. Comprehensive follow-up of car-cinoma patients. J Chron Dis 1971; 24: 179–91.
   PubMedGoogle Scholar
• Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral vs intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–5.
   PubMed Web of Science ®Google Scholar
• McQuellon RP, Muss HB, Hoffman SL, et al. Patient prefer-ences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 1995; 13: 858–68.
   PubMed Web of Science ®Google Scholar
• Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. BMJ 1990; 300: 1458–60.
   PubMed Web of Science ®Google Scholar
• King CR, Haberman M, Berry DL, et al. Quality of life and the cancer experience: The state of the knowledge. Oncol Nurs Forum 1997; 24: 27–41.
   PubMedGoogle Scholar
• Sanders C, Egger M, Donovan J, et al. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998; 317: 1191–4.
   PubMed Web of Science ®Google Scholar
• Moinpour CM. Measuring quality of life: an emerging sci-ence. Semin Oncol 1994; 21 (Suppl 10): 48–63.
   PubMedGoogle Scholar
• de Haes JC, van Knippenberg FC. The quality of life of cancer patients: A review of the literature. Soc Sci Med 1985; 20: 809–17.
   PubMed Web of Science ®Google Scholar
• Feld R. Endpoints in cancer clinical trials: Is there a need for measuring quality of life? Support Care Cancer 1995; 3: 23–7.
   PubMed Web of Science ®Google Scholar
• Gotay CC, Korn EL, Mc Cabe MS, et al. Quality of life assessment in cancer treatment protocols: research issues in protocol development Cancer Inst 1992; 84: 575–9.
   Google Scholar
• Kaasa S. Measurement of quality of life in clinical trials. Oncology 1992; 49: 288–94.
   Google Scholar
• Kiebert GM, Kaasa S. Quality of life in clinical cancer trials: experience and perspective of the European Organization for Research and Treatment Cancer. J Natl Cancer Inst 1996; 20: 91–5.
   Google Scholar
• Maguire P, Selby P. Assessing quality of life in cancer patients. Br J Cancer 1989; 60: 437–40.
   PubMed Web of Science ®Google Scholar
• Spilker B. Introduction. In: Spilker B, ed. Quality of life and Pharmacoeconomics in clinical trials, 2nd edn. Philadelphia: Lippincott-Raven, 1996: 1–40.
   Google Scholar
• Till JE, Sutherland HJ, Meslin EM. Is there a role for preference assessments in research on quality of life in oncology? Qual Life Res 1992; 1: 31–40.
   Google Scholar
• Fallowfield U. Assessment of quality of life in breast cancer. Acta Oncol 1995; 34: 689–94.
   PubMed Web of Science ®Google Scholar
• Lindley C, Vasa S, Sawyer WT, et al. Quality of life and preferences for treatment following systemic adjuvant ther-apy for early-stage breast cancer. J Clin Oncol 1998; 16: 1380–7.
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998; 16: 515–21.
   Google Scholar
• American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996; 14: 671–9.
   PubMed Web of Science ®Google Scholar
• Cella DF. Measuring quality of life in palliative care. Semin Oncol 1995; 22 (Suppl 3): 73–81.
   PubMedGoogle Scholar
• Gunnars B. Quality of life during cancer chemotherapy treatment - an analysis of experience of cancer patients. (dissertation). Lund University, Sweden, 1991: 1–299.
   Google Scholar
• Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic-artery floxuridine infu-sion for colorectal liver metastases. Lancet 1994; 344: 1255–60.
   Google Scholar
• Anderson H, Cottier B, Nicolson M, et al. Phase III study of gemcitabine vs best supportive care in advanced non-small cell lung cancer. The Gemcitabine Study Group. Lung Can-cer 1997; 18 (Suppl 1): 9.
   Google Scholar
• Anderson H, Palmer MK. Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. Br J Cancer 1998; 77: 9–14.
   Google Scholar
• Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: A ran-domised trial: J Clin Oncol 1997; 15: 2403–13.
   Google Scholar
• Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. New Engl J Med 1987; 317: 1490–5.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Zalcberg J R, Rath U, et al. Tomudex (ZD1694): Results of a randomised trial in advanced col-orectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995; 31A: 1945–54.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel-cisplatin vs cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16: 2133–41.
   Google Scholar
• Glimelius B, Hoffman K, Olafsdottir M, et al. Quality of life during cytostatic therapy for advanced symptomatic col-orectal carcinoma: a randomised comparison of two regi-mens. Eur J Cancer Clin Oncol 1989; 25: 829–35.
   PubMedGoogle Scholar
• Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267–74.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Hoffman K, Sjödén P-0, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593–600.
   Google Scholar
• Glimelius B, Ekstrom K, Hoffman K, et al. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163–8.
   PubMed Web of Science ®Google Scholar
• Helsing M, Bergman B, Thaning L, et al. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carbo-platin and etoposide or supportive care only. A multicentre randomised phase III trial. The Joint Lung Cancer Study Group. Eur J Cancer 1998; 34: 1036–44.
   Google Scholar
• Moore MJ, Osoba D, Murphy K, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994; 12: 689–94.
   PubMed Web of Science ®Google Scholar
• Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in operable pancreatic carcinoma. Br J Surg 1994; 81: 882–5.
   PubMed Web of Science ®Google Scholar
• Priestman T, Baum M, Jones V, et al. Comparative trial of endocrine vs cytotoxic treatment in advanced breast cancer. BMJ 1977; 1: 1248–50.
   PubMedGoogle Scholar
• Roszkowski K, Pluzanska A, Krzakowski M, et al. A multi-center, randomized, phase III study of docetaxel plus best supportive care vs best supportive care in chemotherapy-naive patients with metastatic non-resectable localized non-small cell lung cancer. Lung Cancer 2000; 27: 145–7.
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Rosen H, Kornek G-V, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752–5.
   Google Scholar
• Tannock IF, Boyd NF, DeBoer G, et al. A randomised trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377–87.
   PubMed Web of Science ®Google Scholar
• Thongprasert S, Sanguanmitra P, Juthapan W, et al. Rela-tionship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) vs BSC plus chemotherapy. Lung Cancer 1999; 24: 17–24.
   PubMed Web of Science ®Google Scholar
• Aaronson NK. Quality of life research in cancer clinical trials: A need for common rules and language. Oncology 1990; 4: 59–66.
   PubMedGoogle Scholar
• Hunt SM. The problem of quality of life. Qual Life Res 1997; 6: 205–12.
   PubMedGoogle Scholar
• Axelsson B, Sjödén PO. Assessment of quality of life in palliative care. Psychometric properties of a short question-naire. Acta Oncol 1999; 38: 229–37.
   Google Scholar
• Cella DF, Tulsky DS. Measuring quality of life today: Methodological aspects. Oncology (Huntington) 1990; 4: 29–38.
   PubMedGoogle Scholar
• Grant M, Padilla GV, Ferrell BR, et al. Assessment of quality of life with a single instrument. Sem Oncol Nurs 1990; 6: 260–70.
   PubMedGoogle Scholar
• Moinpour CM, Feigl P, Metch B, et al. Quality of life end points in cancer clinical trials: Review and recommenda-tions. J Natl Cancer Inst 1989; 81: 485–95.
   PubMed Web of Science ®Google Scholar
• Selby PJ, Chapman JA, Etazadi-Amoli J, et al. The develop-ment of a method for assessing the quality of life of cancer patients. Br J Cancer 1984; 50: 13–22.
   PubMed Web of Science ®Google Scholar
• Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: McLeod CM, ed. Evaluation of chemotherapeutic agents in cancer. New York: Columbia University Press, 1949: 191–205.
   Google Scholar
• Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and tri-ethylene thiophosphormamide. J Chron Dis 1960; 11: 7–33.
   Google Scholar
• Slevin ML, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988; 57: 109–12.
   PubMed Web of Science ®Google Scholar
• Adams S, Britt DM, Godding PR, et al. Relative contribu-tion of the Karnofsky performance status scale in a multi-measure assessment of quality of life in cancer patients. Psycho Oncol 1995; 4: 239–46.
   Google Scholar
• Sigurdadottir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in pa-tients with generalized malignant melanoma on chemother-apy. Acta Oncol 1996; 35: 149–59.
   Google Scholar
• Sprangers MA, Sneeuw KC. Are healthcare providers ade-quate raters of patients' quality of life - perhaps more than we think? Acta Oncol 2000; 39: 5–8.
   PubMedGoogle Scholar
• Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. Cancer 1991; 67: 844–50.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The Eu-ropean Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in interna-tional clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
   PubMed Web of Science ®Google Scholar
• Cella DF, Tulsky DS, Gray G, et al. The functional assess-ment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 1993; 11: 570–9.
   PubMed Web of Science ®Google Scholar
• Moinpour CM, Hayden KA, Thompson IM, et al. Quality of life assessment in southwest oncology trials. Oncology 1990; 4: 79-84, 89.
   PubMedGoogle Scholar
• Sprangers MA, Cull A, Bjordal K, et al. The European organisation for research and treatment of cancer approach to quality of life assessment: Guidelines for developing ques-tionnaire modules. Qual Life Res 1993; 2: 287–95.
   PubMed Web of Science ®Google Scholar
• King MT, Dobson AJ, Harnett PR. A comparison of two quality of life questionnaires for cancer clinical trials: The functional living index-cancer (FLIC) and the quality of life questionnaire core module (QLQ-C30). J Clin Epidem 1996; 49: 21–9.
   Google Scholar
• Lohr KN, Aaronson NK, Alonso J, et al. Evaluating qual-ity-of-life and health status instruments: development of scientific review criteria. Clin Ther 1996; 18: 979–92.
   PubMed Web of Science ®Google Scholar
• Medical Outcomes Trust: Scientific Advisory Committee. Instrument Review Criteria. MOT Bulletin 1995: 1–4.
   Google Scholar
• Gill TM, Feinstein AR. A critical appraisal of the quality of life measurements. JAMA 1994; 272: 619–26.
   PubMed Web of Science ®Google Scholar
• McGee HM, O'Boyle CA, Hickey A, et al. Assessing the quality of life of the individual: the SEIQoL with a healthy and a gastroenterology unit population. Psychol Med 1991; 21: 749–59.
   PubMed Web of Science ®Google Scholar
• Cella DF. Methods and problems in measuring quality of life. Support Care Cancer 1995; 3: 11–22.
   PubMedGoogle Scholar
• Goodinson SM, Singleton J. Quality of life: A critical review of current concepts, measures and their clinical implications. hit J Nurs Stud 1989; 26: 327–41.
   PubMed Web of Science ®Google Scholar
• Sutherland HJ, Lockwood GA, Boyd NF. Ratings of the importance of quality of life variables: Therapeutic implica-tions for patients with metastatic breast cancer. J Clin Epi-dem 1990; 43: 661–6.
   Google Scholar
• Waldron D, O'Boyle CA, Kearney M, et al. Quality-of-life measurement in advanced cancer. Assessing the individual. J Clin Oncol 1999; 17: 3603–11.
   PubMed Web of Science ®Google Scholar
• Fayers PM, Jones DR. Measuring and analysing quality of life in cancer clinical trials: A review. Stat Med 1983; 2: 429–46.
   PubMedGoogle Scholar
• Hopwood P, Stephens RJ, Machin D. Approaches to the analysis of quality of life data: Experiences gained from a medical research council lung cancer working party palliative chemotherapy trial. Qual Life Res 1994; 3: 339–52.
   Google Scholar
• Levine MN, Guyatt GH, Gent M, et al. Quality of life in stage II breast cancer: An instrument for clinical trials. J Clin Oncol 1988; 6: 1798–810.
   PubMed Web of Science ®Google Scholar
• List MA, Ritter-Sterr C, Lansky SB. A performance status scale for head and neck cancer patients. Cancer 1990; 66: 564–9.
   PubMed Web of Science ®Google Scholar
• Sullivan BA, Pharm D, McKinnis R, et al. Quality of life in patients with metastatic colorectal cancer receiving chemotherapy: A randomized, double-blind trial comparing 5-FU vs 5-FU with leucovorin. Pharmacother 1995; 15: 600–7.
   PubMedGoogle Scholar
• Cella DF, Bonomi AE. Measuring quality of life: update. Oncology 1995; 9 (Suppl 11): 47–60.
   PubMedGoogle Scholar
• Clark A, Fallowfield U. Quality of life measurements in patients with malignant disease: A review. Roy Soc Med 1986; 79: 165–9.
   Google Scholar
• Donovan K, Sanson-Fisher RW, Redman S. Measuring quality of life in cancer patients. J Clin Oncol 1989; 7: 959–68.
   PubMed Web of Science ®Google Scholar
• The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 66–72.
   PubMed Web of Science ®Google Scholar
• Montazeri A, Gillis CR, McEwen J. Measuring quality of life in oncology: Is it worthwhile? II. Experiences from the treatment of cancer. Eur J Cancer Care 1996; 5: 168–75.
   Google Scholar
• Selby P, Robertson B. Measurement of quality of life in patients with cancer. Cancer Surveys 1987; 6: 521–43.
   PubMedGoogle Scholar
• Stenstrup EZ. Review of quality of life instrumentation in the oncology population. Clinical Nurse Specialist 1996; 10: 164–9.
   PubMedGoogle Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depres-sion scale. Acta Psychiatr Scand 1983; 67: 361–70.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Townsend M, Berman LB, et al. A comparison of Likert and visual analogue scales for measuring change in function. J Chron Dis 1987; 40: 1129–33.
   PubMedGoogle Scholar
• Mickelson H, Bolund C, Nilsson B, et al. Health-related quality of life measure by the EORTC QLQ-C30. Reference values from a large sample of the Swedish population. Acta Oncol 2000; 39: 477–84.
   Google Scholar
• Cella DF. Manual for the Functional Assessment of Cancer Therapy (FACT) Quality of life instrument (Version 4). Evanston Northwestern Healthcare Illinois 1997.
   Google Scholar
• Schag CA, Ganz PA, Wing DS, et al. Quality of life in adult survivors of lung, colon and prostate cancer. Qual Life Research 1994; 3: 127–41.
   PubMed Web of Science ®Google Scholar
• Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: The Functional Living Index - Cancer: Development and validation. J Clin Oncol 1984; 2: 472–83.
   PubMed Web of Science ®Google Scholar
• de Haes JC, Raatgever JW, van der Burg ME, et al. Evalua-tion of the quality of life of patients with advanced ovarian cancer treated with combination chemotherapy. In: Aaronson NK, Beckmann J, eds. The quality of life of cancer patients. New York: Raven Press, 1987: 215–26.
   Google Scholar
• Baum M, Priestman T, West RR, et al. A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Eur J Cancer 1980; 16 (Suppl 1): 223–6.
   PubMedGoogle Scholar
• Priestman TJ, Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1976; 24: 899–901.
   Google Scholar
• Coates A, Dillenbeck CF, McNeil DR, et al. On the receiv-ing end-II. Linear Analog Self Assessment (LASA) in evalu-ation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol 1983; 19: 1633–7.
   Google Scholar
• Ferrans CE, Powers MJ. Quality of life index: Development and psychometric properties. Adv Nurs Sci 1985; 8: 15–24.
   PubMed Web of Science ®Google Scholar
• Ferrans CE. Development of a quality of life index for patients with cancer. Oncol Nurs Forum 1990; 17 (Suppl 3): 15–9.
   PubMedGoogle Scholar
• Ferrans CE, Powers MJ. Psychometric assessment of the quality of life index. Res Nurs Health 1992; 15: 29–38.
   PubMed Web of Science ®Google Scholar
• Padilla GV, Presant C, Grant MM, et al. Quality of life index for patients with cancer. Res Nurs Health 1983; 6: 117–26.
   PubMed Web of Science ®Google Scholar
• Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997; 33 (Suppl 1): 18–22.
   Google Scholar
• Hoffman K, Glimelius B. Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer. Acta Oncol 1998; 37: 651–9.
   PubMed Web of Science ®Google Scholar
• Williams A. Economics of coronary artery bypass grafting. BMJ 1985; 291: 326–9.
   PubMed Web of Science ®Google Scholar
• Gelber RD, Goldhirsch A. A new endpoint for the assess-ment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986; 4: 1772–9.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Gelber RD, Simes RJ, et al. Costs and benefits of adjuvant therapy in breast cancer. A quality-ad-justed survival analysis. J Clin Oncol 1989; 7: 36–44.
   PubMed Web of Science ®Google Scholar
• Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer clinical trials: serious problems and chal-lenges. Stat Med 1998; 17: 517–32.
   PubMed Web of Science ®Google Scholar
• Bernhard J, Hfirny C, Maibach R, et al. Quality of life as subjective experience: Reframing of perception in patients with colon cancer undergoing radical resection with or with-out adjuvant chemotherapy. Ann Oncol 1999; 10: 775–82.
   PubMed Web of Science ®Google Scholar
• Klee MC, King MT, Machin D, et al. A clinical model for quality of life assessment in cancer patients receiving chemotherapy. Ann Oncol 2000; 11: 23–30.
   PubMedGoogle Scholar
• Schwartz CE, Sprangers MAG. Methodological approaches for assessing response shift in longitudinal health-related quality-of life research. In: Schwartz & Sprangers, editors. Adaptation to changing health. Response shift in quality-of-life research, Am Psychol Assoc, Wash DC; 2000; 21–108.
   Google Scholar
• Sprangers MA, Van Dam FS, Broersen J, et al. Revealing response shift in longitudinal research on fatigue. The use of the then test approach. Acta Oncol 1999; 6: 709–18.
   Google Scholar
• Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139–44.
   PubMed Web of Science ®Google Scholar
• Ware KE Jr, Snow KK, Kosinski M, et al. SF-36 Health Survey Manual and Interpretation Guide. New England Medical Center. The Health Institute 1993.
   Google Scholar
• Moinpour CM, Sawyers Triplett J, Mcknight B, et al. Chal-lenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psycho-Oncol 2000; 9: 340–54.
   PubMed Web of Science ®Google Scholar
• Fairclough DL. Summary measures and statistics for com-parison of quality of life in clinical trial of cancer therapy. Stat Med 1997; 16: 1197–209.
   PubMed Web of Science ®Google Scholar
• Stat Med 1998; 17: 517–796.
   Google Scholar
• Consensus Statement Cytostatic Drug Treatment in Ad-vanced Cancer, Stockholm: MFR, Spri 1990.
   Google Scholar
• Norges Offentliga Utredningar. Care and knowledge. Norsk Kreftplan 1997. (in Norwegian) NOU 197:20.
   Google Scholar
• Rubens RD, Towlson KE, Ramirez AJ, et al. Appropriate chemotherapy for palliating advanced cancer. BMJ 1992; 304: 35–40.
   PubMed Web of Science ®Google Scholar